The new insulin analogues and oral diabetes medicines have been associated with high expenditures, both for individuals and governments (Beran et al., 2018) and the cost of these medicines are considered a major challenge in accessing these medicines particularly in low- and middle-income countries (LMICs) (McEwen et al., 2017). This evidence concerns the gene INS and diabetes mellitus.